CyPass 睫状体上腔微支架在原发性开角型青光眼中的安全性和有效性:COMPASS XT 研究 5 年结果
COMPASS XT 是 COMPASS 随机临床试验的 3 年安全性扩展研究,评估超声乳化联合 CyPass 微支架植入(n=215)与单纯超声乳化(n=67)术后 36、48、60 个月的安全性和有效性。主要终点为威胁视力的眼部不良事件,结果显示此类事件罕见且与微支架无关,两组不良事件频率相似;60 个月时微支架组达到眼压降低≥20% 且不使用降压药物的比例高于对照组(46% vs 32.1%)。
要点
- 威胁视力的严重眼部不良事件共 3 例,微支架组 2 例、对照组 1 例,均与微支架装置无关。
- 两组不良事件频率相似,最常见为较 COMPASS 最佳 BCVA 下降≥2 行和较第 24 个月 VFMD 恶化≥2.5 dB。
- 60 个月时微支架组 46%(95%CI 38.9%-53.2%)vs 对照组 32.1%(95%CI 19.9%-46.3%)达到眼压降低≥20% 且不用降压药。
核心结论
- 微支架植入后威胁视力的严重眼部不良事件少,角膜失代偿的临床证据极少。
研究设计与样本
- COMPASS 随机临床试验的 3 年安全性扩展研究,随访至术后 60 个月。
- 纳入 COMPASS 多中心试验中行微支架植入联合超声乳化(n=215)或单纯超声乳化(n=67)的患者。
- 在术后 36、48、60 个月进行评估,主要终点为威胁视力的眼部不良事件。
主要发现
- 威胁视力的眼部不良事件共 3 例,微支架组 2 例、对照组 1 例,均与微支架装置无关。
- 两组眼部不良事件频率相似,最常见为较 COMPASS 最佳 BCVA 下降≥2 行和较第 24 个月 VFMD 恶化≥2.5 dB。
- 两组平均 BCVA 较基线变化、临床检查、角膜厚度测量和 VFMD 相似。
- 60 个月时微支架组 46%(95%CI 38.9%-53.2%)vs 对照组 32.1%(95%CI 19.9%-46.3%)达到眼压降低≥20% 且不使用降压药物。
关键数值与推荐
- 主要终点为威胁视力的眼部不良事件发生情况。
- 60 个月时达到眼压降低≥20% 且不使用降压药物的受试者比例:微支架组 46%(95%CI 38.9%-53.2%)vs 对照组 32.1%(95%CI 19.9%-46.3%)。
- 不良事件中最常见为较 COMPASS 最佳 BCVA 下降≥2 行和较第 24 个月 VFMD 恶化≥2.5 dB。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To characterize the long-term (up to 5 years) safety and effectiveness of the supraciliary Micro-Stent (Alcon) implanted at the time of phacoemulsification in eyes with coexisting open-angle glaucoma (OAG) and visually significant cataract. DESIGN: Three-year safety extension of a 2-year randomized clinical trial. METHODS: Patients from the multicenter Study of an Implantable Device for Lowering Intraocular Pressure in Glaucoma Patients Undergoing Cataract Surgery (COMPASS) trial who underwent Micro-Stent implantation plus phacoemulsification (n = 215) or phacoemulsification alone (n = 67) were evaluated 36, 48, and 60 months postoperatively. The primary outcome measurement was the occurrence of sight-threatening ocular adverse events. Evaluations at each time point included best-corrected visual acuity (BCVA), anterior and posterior segment examinations, tonometry, gonioscopy, pachymetry, perimetry, specular microscopy, and assessment of adverse events. RESULTS: Three sight-threatening ocular adverse events occurred, 2 in the Micro-Stent group and 1 in the control group, but none of these events was related to the Micro-Stent device. Ocular adverse events were of similar frequencies in both groups, the most common of which were BCVA loss of ≥2 lines compared with best BCVA in COMPASS and worsening of visual field mean defect (VFMD) ≥2.5 dB compared with month 24. Changes in mean BCVA from baseline, clinical examinations, pachymetry, and VFMD were similar in the 2 groups. At 60 months, a higher proportion of subjects in the Micro-Stent group (46%; 95% confidence interval [CI], 38.9%-53.2%) than in the control group (32.1%; 95% CI 19.9%-46.3%) were able to achieve a reduction of ≥20% in intraocular pressure without using hypotensive medication. CONCLUSIONS: Few sight-threatening serious ocular adverse events occurred following Micro-Stent implantation, and clinical evidence of corneal decompensation was minimal.
引用
- Reiss G, Clifford B, Vold S, et al. Safety and Effectiveness of CyPass Supraciliary Micro-Stent in Primary Open-Angle Glaucoma: 5-Year Results from the COMPASS XT Study. Am J Ophthalmol. 2019. PMID: 31377287. doi:10.1016/j.ajo.2019.07.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。